352 results about "Lacceroic acid" patented technology

The invention discloses a high-stability hydroxysteroid dehydrogenase mutant, a co-immobilized enzyme construction method and application. According to the invention, a site-directed mutant library is constructed based on computer-aided design, and mutants with significantly improved thermal stability and greatly improved catalytic efficiency compared with wild type mutants are obtained through screening; meanwhile, a co-immobilized enzyme construction method based on electrostatic adsorption and chemical crosslinking is established, the hydroxysteroid dehydrogenase mutant and lactic dehydrogenase are co-immobilized, the co-immobilized enzyme can still keep high activity under high substrate concentration, and the conversion rate is still maintained to be 90% or above after 30 batches of co-immobilized enzyme are repeatedly used. And an important foundation is laid for industrial application of the hydroxysteroid dehydrogenase.

The invention discloses a high-temperature-resistant and salt-resistant fracturing fluid and a preparation method thereof, and relates to the technical field of oil field fracturing fluids. When the high-temperature-resistant and salt-resistant fracturing fluid is prepared, sodium 3-chloro-2-hydroxypropane sulfonate, N, N-dimethylacrylamide and ethylene glycol react to prepare a quaternized solid product, and then the quaternized solid product reacts with 1-bromooctadecane to prepare an amphoteric hydrophobic monomer; guar gum powder reacts with 3-(1-naphthyloxy)-1, 2-epoxypropane to prepare naphthyloxy functionalized guar gum, and then the naphthyloxy functionalized guar gum, acrylamide and an amphoteric hydrophobic monomer are subjected to initiated polymerization through ceric ammonium nitrate to prepare modified guar gum; enabling zirconium oxychloride octahydrate, titanium chloride, lactic acid, ethanediamine and glycerol to react to prepare an organic zirconium cross-linking agent; and finally, mixing the modified guar gum, an organic zirconium cross-linking agent, sodium thiosulfate, sodium bromate, a surfactant and water to prepare the high-temperature-resistant and salt-resistant fracturing fluid. The high-temperature-resistant and salt-resistant fracturing fluid prepared by the invention has excellent high-temperature resistance and salt resistance.

The invention discloses an application of beta-alanine in preparation of a medicine for treating pulmonary arterial hypertension. In-vivo and in-vitro pharmacological experiments prove that beta-alanine can inhibit lactic acid-mediated histone milk acylation modification and hypoxia-induced phenotypic transformation of PASMCs (Polyaspartic Sulfonate Molecules); the hemodynamics and pulmonary artery vascular remodeling of the PAH mouse are improved. The beta-alanine can inhibit phenotypic transformation of PASMCs and reverse pulmonary artery vascular remodeling which is a key pathological change in the pulmonary hypertension generation process, has huge potential in treatment of pulmonary hypertension, and has good application prospects and high clinical application value.

The invention relates to a polygonatum sibiricum probiotic compound preparation with an aging delaying effect and application thereof. The compound preparation comprises a polygonatum sibiricum extract and a probiotic composition, the bacterial strains in the probiotic composition comprise a combination of a bifidobacterium animalis subsp. Lactis BLa36 bacterial strain, a bifidobacterium longum BL21 bacterial strain, a bifidobacterium adolescentis BAC30 bacterial strain, a lactobacillus plantarum Lp90 bacterial strain, a lactobacillus casei LC89 bacterial strain, a bifidobacterium breve BBr60 bacterial strain and a pediococcus acidilactici CCFM7902 bacterial strain. After the rhizoma polygonati component and the probiotic component are combined for use, the rhizoma polygonati component and the probiotic component have potential synergistic effects in the aspects of improving the intestinal flora structure, regulating the intestinal environment, delaying senescence, reducing inflammation-related symptoms and the like. Moreover, further, various probiotic strains are compounded and combined for use, so that the capability of a related compound preparation in the aspect of delaying various symptoms of senescence can also be improved in a combined manner.

The invention belongs to the field of pet food processing, and relates to a functional pet food for regulating intestinal health and a preparation method thereof. The functional pet food can increase MTL content in dog serum in a physiological range, reduce DAO activity and D-lactic acid and LPS content in dog serum, improve intestinal mucosa barrier function, and significantly improve dog intestinal health. The functional pet food can shorten gastrointestinal transmission time and effectively improve constipation. The functional pet food disclosed by the invention has a good effect in the aspects of treating diarrhea and constipation, and has a two-way regulation effect in regulating intestinal flora imbalance. The components of the raw materials have a synergistic effect, the nutrition is balanced, the preparation method is simple, the palatability is optimally designed, and the metabolic characteristic is free of burden, so that pets can safely take the feed for a long time, a convenient and efficient preventive health management scheme is provided for family pet raising, and the feed has a relatively good commercial application prospect.

A system includes a wearable device including a base adapted to be connected to skin of a patient. An electrochemical sensor is connected to the base. The electrochemical sensor includes a sensor medium responsive to lactate. The electrochemical sensor is in fluid connection with one or more transdermal fluid paths in connection with the base. The one or more transdermal fluid paths are configured to be placed in fluid connection with the subdermal fluid of the patient. The system further includes electronic circuitry including at least one measurement system in operative connection with the electrochemical sensor to measure a variable providing a measure of change in at least one property of the sensor medium which is dependent upon the presence of lactate in the subdermal fluid.

The invention discloses application of lycium barbarum polysaccharide in preparation of a medicine for inhibiting methylamphetamine-induced nerve injury, and relates to the technical field of biological medicines. It is found and proved that lycium barbarum polysaccharide can inhibit methylamphetamine-induced nerve injury, and the effect is remarkable. From the aspect of cell survival, the survival rate of the microglial cells pretreated by the lycium barbarum polysaccharide after METH stimulation is obviously improved. In the molecular mechanism, the lycium barbarum polysaccharide can effectively lower the protein expression level of the METH-induced pyroptosis marker, the content of inflammatory factors IL-1beta and IL-18 can be reduced, and the release of lactic dehydrogenase is reduced. The result shows that the lycium barbarum polysaccharide can alleviate inflammatory response by inhibiting NLRP3 / ASC pathway mediated microglial cell pyroptosis, thereby inhibiting METH-induced nerve injury. The invention provides a new direction for developing METH neurotoxicity intervention medicines.

The present disclosure provides methods of treating an immune-mediated disease in a subject in need thereof. The present disclosure provides methods of treating atopic dermatitis in a subject in need thereof. The present disclosure provides methods of treating moderate to severe atopic dermatitis in a subject in need thereof. The present disclosure provides a method of treating atopic dermatitis (AD) in a subject in need thereof, the method comprises selecting a subject suffering from AD and having an elevated level relative to a control of at least one biomarker selected from the group consisting of thymus activation regulatory chemokine (TARC), interleukin-5 (IL-5), eosinophilic granulocyte count, and lactic dehydrogenase (LDH).

The application relates to the frontiers of nanomaterials and drug screening fields, and discloses a fluorescent probe material for drug screening and a drug screening method. The fluorescent probe material realizes screening of anticancer drug efficacy of a to-be-detected drug by detecting the concentration of an NAD+ (nicotinamide adenine dinucleotide) active marker of lactate dehydrogenase, the fluorescent probe material comprises an A agent and a B agent, the A agent is a covalent organic framework material loaded with carbon dots with reducibility, and is denoted as COF@CDs, and the B agent is a transition metal hydride; the transition metal hydride can make NAD+ hydrogenated and reduced into NADH in the presence of the COF@CDs; the product after hydrogen loss of the transition metal hydride can be combined with the COF@CDs, and the COF@CDs can emit fluorescence under excitation light, and the fluorescence is quenched.

SOLVENT COMPOSITIONS The present invention relates to a solvent composition for solvent-based paints or other coatings characterized in that it comprises a combination of dimethyl glutarate and at least one other compound selected from isobutyl acetate, ethyl lactate, dimethyl 2-methylglutarate, 2-methyltetrahydrofuran, ethyl acetate, cyclopentyl methyl ether, dithoxymethane, dimethyl carbonate, dimethyl succinate, benzyl alcohol, dimethyl adipate, and glyceryl triacetate. Fig. 1

The invention discloses Leishan fish sauce sour essence as well as a preparation method and application thereof. The leishan fish sauce acid essence is prepared from ethyl acetate, absolute ethyl alcohol, ethyl isovalerate, ethyl hexanoate, isoamyl alcohol, furfuryl alcohol, ethyl lactate, ethyl caprylate, acetic acid, diethyl succinate, methyl salicylate, ethyl benzoate, ethyl laurate, hexanoic acid, phenethyl alcohol, 4-methyl guaiacol, ethyl myristate, ethyl palmitate, ethyl oleate, capsicum oleoresin, ethyl phenylacetate and ginger oil. And lactic acid, glycerol triacetate, ocimene, ethyl isovalerate, ethyl butyrate, anethole and phenylacetaldehyde. The Leishan fish sauce sour essence disclosed by the invention is soft and harmonious in overall fragrance, natural and vivid, still has stable flavor characteristics at high temperature, can make up the problem of flavor deficiency in sour soup products, realizes accurate reproduction and controllable release of composite fragrance, improves the standardization level of products, and effectively improves the preference degree of consumers.

The invention aims to provide a method for determining the content of main effective components of Xiaoyianmi cream and an application of the method, and aims to solve the technical problem that a Xiaoyianmi cream compound preparation is lack of efficient and accurate multi-component synchronous quality evaluation due to complex components of the Xiaoyianmi cream compound preparation. According to the method, a chromatography-tandem mass spectrometry technology is adopted, chromatography and mass spectrometry conditions are optimized, and an analysis method for simultaneously determining six components such as phloridine, piperlonguminine, piperine, N-trans-feruloyltyramine, DL-B-phenyllactic acid and pinocembrin is established. The determination method provided by the invention has the advantages of being simple and convenient to operate, high in sensitivity, good in repeatability, high in accuracy and the like, can realize rapid and synchronous determination of multi-index components in the Xiaoyi honey paste, and provides reliable technical support for quality control and standardization of the Xiaoyi honey paste.

The application discloses a composition with long-acting anti-wrinkle, skin elasticity improvement and skin tightening effects, a preparation method and application thereof, and belongs to the technical field of cosmetics. The composition comprises the following efficacy components: Schizosaccharomyces pombe ferment lysate, hydroxypropyl tetrahydropyrane triol, lactose, whey protein, lactic acid, Lactarius volemus extract and palm leaf tree extract. The eye cream prepared by using the composition has very significant long-acting anti-wrinkle, skin elasticity improvement and skin tightening effects. After 28 days of use, the R2 value of skin elasticity at the corner of the eye is increased by more than 20%, the R0 value of total skin stretching displacement is decreased by more than 40%, the proportion of wrinkle area is decreased by more than 15%, and the wrinkle depth is decreased by more than 27%. The effect after 28 days of use is also significantly better than that after 14 days of use.

The invention belongs to the technical field of gene engineering and protein engineering, and particularly relates to a fully human antagonistic antibody taking a lactylated STAT6 protein as a target spot and application of the fully human antagonistic antibody. According to the present invention, the completely humanized antagonistic antibody using the lactylated STAT6 protein as the target spot is screened from the human scFv phage antibody library, the amino acid sequence of the completely humanized antagonistic antibody is represented by SEQ ID NO: 1, and the completely humanized antagonistic antibody has the specificity of the targeted lactylated STAT6 protein, and has the application prospect in preparation of the product for diagnosis, treatment or alleviation of sepsis immunosuppression.

The invention belongs to the field of in-vitro diagnostic reagents, and particularly relates to application of a reagent for detecting biomarkers in serum in preparation of a cerebral arterial thrombosis diagnostic kit. The invention determines that the concentrations of lactic acid, isoleucine, fumaric acid, ketoglutaric acid, hypoxanthine, tyrosine, histidine and inosine in serum of a cerebral arterial thrombosis (IS) patient are significantly related to major atherosclerosis (LAA) and minor artery occlusion (SAO), so that the concentrations of the biomarkers can be used as a basis for diagnosing IS and distinguishing LAA and SAO.

The application discloses a nisin protective agent containing ectoine and application, and belongs to the technical field of nisin storage and application. The nisin protective agent containing ectoine comprises ectoine, pullulan and 2-hydroxybutanedioic acid in a mass percentage ratio of 20-70%, 10-50% and 10-40% respectively. The preparation method comprises the following steps: ectoine, pullulan and 2-hydroxybutanedioic acid are weighed according to the mass percentage ratio, uniformly mixed in a mixer, and then ground in a grinder at 20-30 DEG C to a particle size of 100-200 nm, so that the nisin protective agent containing ectoine with uniform quality is obtained. The application can significantly improve the stability of nisin in the storage and application process.

The invention provides application of an intracellular lactic acid level increasing agent in preparation of a drug for enhancing sensitivity of BRAF V600E mutant tumors to a BRAF inhibitor or in preparation of a drug for treating BRAF V600E mutant tumors resistant to the BRAF inhibitor. According to the invention, the intracellular lactic acid concentration is improved by using an intracellular lactic acid level improver, SUMOylation of BRAFV600E protein is promoted, and the BRAFV600E protein is locked in an open drug sensitive conformation; in-vivo and in-vitro experiments prove that the combination of the MCT4 inhibitor and the BRAF inhibitor (such as vimofenib) has a remarkable synergistic anti-tumor effect, drug resistance can be effectively relieved, and a new treatment strategy is provided for refractory colorectal cancer and the like.

An object of the present disclosure is to provide a novel animal nutritional composition. The disclosure is directed to a racehorse nutritional composition, an animal nutritional composition for reducing an elevation of blood lactic acid concentrations, and an animal nutritional composition for coat improvement, each of which contains nicotinamide mononucleotide.

This invention proposes a combined inhibitor for separating bastnaesite and monazite, along with its method and application. The raw materials for the combined inhibitor include small organic molecules and microbial polysaccharides; the small organic molecules include one or more of oxalic acid, malic acid, tartaric acid, lactic acid, succinic acid, and citric acid; the microbial polysaccharides include one or more of currant gum, guar gum, xanthan gum, and gellan gum. This invention achieves highly selective inhibition of monazite on the mineral surface through the synergistic adsorption and action of the inhibitor, with small organic molecules and microbial polysaccharides as the main components, thereby efficiently separating bastnaesite under mild flotation conditions. It offers advantages such as good selectivity, strong action, low reagent cost, and environmental friendliness.

The invention discloses a loose macroporous iron-based nano catalytic compound for inducing tumor para-apoptosis and a preparation method and application thereof.The nano catalytic compound (TF-Fe at LC) is prepared by taking a porous Fe3O4 nano cluster composed of single crystals as a carrier, modifying the surface of the carrier with an acid-responsive tannic acid-iron (TA-Fe < 3 + >) network and co-loading lactate oxidase (LOD) and a mitochondrial uncoupling agent CCCP in the carrier. The TF-Fe-coated LC constructed by the invention does not need additional chemotherapeutic drugs, and tumor cells are induced to generate a large amount of active oxygen through catalytic cascade and mitochondrial oxidative stress, so that parapoptosis of the tumor cells is triggered; the parapoptotic cells can play a role of a tumor vaccine, induce other tumor cells to generate immunogenic death, and activate an organism immune system to recognize and kill tumors. In addition, the nano catalytic system can be combined with drugs and immunosuppressants to realize a synergistic anti-tumor effect.

The invention belongs to the field of pharmaceutical preparations, and provides a medical composition for treating premature delivery and a preparation method thereof. The progesterone nanocrystal (D50 is 250-350 nm) and poloxamer 407 / 188 thermosensitive gel-forming system composite design is adopted, hydroxypropyl methylcellulose or carbomer 974P and a functional adhesion polymer (carbomer-cysteine or carbomer-catechol) are matched, the pH is adjusted to 4.0-4.5 through a lactic acid / sodium lactate buffer system, and the progesterone nanocrystal / poloxamer composite gel-forming agent is prepared. The excellent performance that the sol-gel transition temperature is 30-34 DEG C, the elastic modulus is not smaller than 150 Pa at 37 DEG C, the modulus retention rate is not smaller than 60% after the emulsion is diluted by 5-10 times, the adhesion work is not smaller than 0.60 N.s, and the anti-flushing retention rate is not smaller than 70% after the emulsion is diluted by 5-10 times is achieved. The invention solves the problem of synergy of high-modulus gel strength, rapid self-repairing ability and anti-dilution and anti-flushing stability, realizes unification of long-acting drug release and excellent biological adhesion performance in vagina physiological fluid dilution and mechanical flushing environments, and has wide clinical application value.

The invention provides an application of Exifenone in preparation of a medicine for treating diabetic retinopathy, the Exifenone can be combined near a K412 lactic acid modification site of HDAC1, so that the lactic acid modification of the K412 site of the HDAC1 is specifically inhibited, the deacetylation activity of the HDAC1 to H3K56 is enhanced, the transcriptional activation of VEGFA (vascular endothelial growth factor A) mediated by H3K56ac and pathological angiogenesis are inhibited, and the effect of treating diabetic retinopathy is achieved. Further, vascular pathological injury caused by diabetic retinopathy is improved. The application provides a new target and a candidate drug for clinical treatment of diabetic retinopathy. The research result of the application provides experimental evidence for the epoxybenzophenone to be used for clinical specific treatment of diabetic retinopathy.

A use of intestinal bacteria that co-produce D-lactate and a metabolite thereof D-lactate in predicting exercise capacity. The intestinal bacteria that co-produce D-lactate and the metabolite thereof D-lactate affect the levels of the exercise-related hormones dopamine and adrenaline, thereby significantly impairing exercise capacity. The intestinal bacteria that co-produce D-lactate and the metabolite thereof D-lactate are markers that can be used for routine exercise monitoring and for regulating exercise tolerance.

The invention relates to the technical field of blood detection, in particular to a formula of an optimized alanine aminotransferase kit, which has the technical scheme that lactic dehydrogenase, NADH (nicotinamide adenine dinucleotide), DCA-Na, glycerol and a Proclin-300 preservative are dissolved in a reagent I Tris buffer solution of the ALT kit; l-alanine, alpha-ketoglutaric acid, glycerol and a Proclin-300 preservative are dissolved in a Tris buffer solution of the reagent II, DCA-Na in the kit is an activator of a pyruvate-lactic dehydrogenase compound and inhibits the kinase activity of pyruvate dehydrogenase, glycerol is an enzyme activity stabilizer, Proclin-300 is a preservative, an instrument is used for detection at the main wavelength of 340 nm and the auxiliary wavelength of 380 nm, and the detection result is accurate. And calculating the ALT activity according to the decreasing rate of NADH (nicotinamide adenine dinucleotide).

Nicotine-containing formulations for electric / electronic nicotine delivery systems are disclosed, containing both nicotine at relatively much higher concentrations, typically at least 25% by weight of total formulation weight, w / w, and in many cases as much as 40-50% w / w, than is typical for conventional nicotine containing formulations, which only contain about 2-4% w / w nicotine. The formulations also include a biologically and pharmaceutically acceptable mono- or di-carboxylic organic acid, such as benzoic acid, salicylic acid and most preferably lactic acid also at relatively high w / w concentrations. One or more nicotine salts may be created and be extant within the formulations, which not only mitigates against the loss of nicotine to the atmosphere through natural volatility and evaporation, but also markedly increases the surface energy of the formulations created, and the globules of formulations deposited on a heating substrate are much more cohesive and much less likely to migrate through wetting over the substrate.

The invention provides a nicotine salt and a preparation method thereof, an atomization matrix, a device and a buccal product, the preparation method comprises the following steps: costustolic acid, nicotine and a catalyst are mixed for a reaction to obtain a reaction solution containing the nicotine salt, the catalyst is 4-dimethylaminopyridine, dicyclohexylcarbodiimide, protease, lipase or pectinase; and purifying the reaction liquid to obtain the nicotine salt. As the costus acid has the smell of costustoot, the salt formed by the costus acid and the nicotine has no obvious peculiar smell. The chemical structure of the costus acid does not contain benzene rings, the toxicity of salt formed by the costus acid and nicotine is smaller than that of nicotine benzoate and nicotine lactate, and harm to the human body is lower. The nicotine salt synthesized by the costus acid and the nicotine is larger in molecular weight, weaker in volatility and higher in thermal stability. The pKa value of costus acid is larger than that of benzoic acid and lactic acid, salt formed by costus acid and nicotine is close to neutral, and irritation can be reduced. The synthesis yield is high, the toxicity is low, and the heating wire is difficult to corrode.

The invention relates to a metabolite marker for early diagnosis of colorectal cancer as well as application and a device of the metabolite marker. The marker comprises sulfate, ubiquinone-1, a deoxycholic acid glycine conjugate, demethylchlorophyllin, 3-(3, 5-diiodine-4-hydroxyphenyl) lactate, vitamin K1, O-decanoyl-L-carnitine, sedoheptulose 1, 7-diphosphoric acid, cholesterol-docosahexaenoic acid ester and acyl AMP (adenosine monophosphate). The marker combination has excellent performance in colorectal cancer detection, AUROC can reach 0.97, and noninvasive screening and early diagnosis of colorectal cancer can be accurately, quickly and simply realized.

This invention discloses a composition for relieving allergies, itching, and improving rough skin, its preparation method, and its application. The composition comprises the following active ingredients: asiaticoside, centella asiatica extract, kava extract, aescin, allantoin, and sodium hyaluronate. This invention prepares the composition using raw materials and proportions containing asiaticoside, centella asiatica extract, kava extract, aescin, allantoin, and sodium hyaluronate. The synergistic effect between these components results in excellent anti-allergic, anti-itch, and skin-roughening effects. After preparing the composition into a soothing and anti-itch cream, tests showed that it significantly reduced the a* value and lactic acid stinging score of sensitive skin. Doctor evaluation methods further confirmed its significant improvement effects on burning, erythema, swelling, peeling, stinging, and itching of sensitive skin, while also showing a significant effect on improving rough skin.